Clinical Trials
35 trialsNCT03382977 2026-05-08
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
VBI Vaccines Inc.
Phase 1/2 Terminated
NCT05275478 2026-04-15
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
Tango Therapeutics, Inc.
Phase 1/2 Terminated
NCT02942264 2026-02-23
Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT03330197 2025-08-12
A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG
Alaunos Therapeutics
Phase 1/2 Terminated
NCT05388435 2025-05-04
Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients
SK Life Science, Inc.
Phase 1/2 Terminated
NCT05737212 2025-02-21
Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients With Recurrent High-grade Gliomas
Dawonmedax Co., Ltd.
Phase 1/2 Terminated
NCT04421378 2024-12-16
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
Karyopharm Therapeutics Inc
Phase 1/2 Terminated
NCT00555399 2024-08-22
Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT05370508 2024-07-26
A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM
SonALAsense, Inc.
Phase 1/2 Terminated
NCT04915404 2024-06-06
Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV)
WPD Pharmaceuticals Sp. z o.o.
Phase 1/2 Terminated
NCT02085304 2024-04-19
Tumor Resection and GliadelĀ® Wafers, Followed by TemodarĀ® With Standard Radiation or GammaKnifeĀ® for New GBM
St. Joseph's Hospital and Medical Center, Phoenix
Phase 1/2 Terminated
NCT02829723 2024-01-18
A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors
Novartis
Phase 1/2 Terminated
NCT01721577 2023-05-22
AXL1717
Rush University Medical Center
Phase 1/2 Terminated
NCT03119064 2022-12-13
329
Brown University
Phase 1/2 Terminated
NCT01884740 2022-08-09
Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22
Weill Medical College of Cornell University
Phase 1/2 Terminated
NCT00479765 2022-06-22
A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGelā¢ in Subjects With Recurrent Glioma
Boston Scientific Corporation
Phase 1/2 Terminated
NCT00669669 2022-05-18
O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT01110876 2021-08-25
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT02765165 2021-07-23
Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)
Proximagen, LLC
Phase 1/2 Terminated
NCT02046187 2021-06-16
Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma
St. Joseph's Hospital and Medical Center, Phoenix
Phase 1/2 Terminated
NCT02709889 2020-10-19
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
AbbVie
Phase 1/2 Terminated
NCT01582152 2019-06-05
Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT01044966 2019-02-12
A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma
Medical University of South Carolina
Phase 1/2 Terminated
NCT01870726 2018-05-30
Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma
Novartis
Phase 1/2 Terminated
NCT01666600 2017-11-01
NOA-12: BIBF1120 and R-RT in Glioblastoma
University Hospital Heidelberg
Phase 1/2 Terminated
NCT00456612 2017-03-06
Radiosurgery for Glioblastoma Multiforme
Beth Israel Deaconess Medical Center
Phase 1/2 Terminated
NCT02025231 2017-02-08
Image Guided Reirradiation of High-grade Glioma
Rigshospitalet, Denmark
Phase 1/2 Terminated
NCT01189240 2015-12-14
RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT01205334 2013-08-26
COGLI
Baylor College of Medicine
Phase 1/2 Terminated
NCT00650949 2013-05-03
Efficacy Study of CYT997 in Combination With Carboplatin in Glioblastoma
Gilead Sciences
Phase 1/2 Terminated
NCT00005856 2013-01-24
Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT00948389 2012-08-31
Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT00376103 2009-09-18
Radiation Boost for Newly Diagnosed Glioblastoma Multiforme
Methodist Healthcare
Phase 1/2 Terminated
NCT00115453 2008-08-18
Boron Neutron Capture Therapy (BNCT) as Treatment of Glioblastoma
Boneca Corporation
Phase 1/2 Terminated